Obesity treatment enters a new era amid calls for caution in the use of diabetes medications

This news has been read 887 times!

KUWAIT CITY, Nov 24, (Agencies): The landscape of obesity treatment has entered a transformative phase, propelled by medications initially designed to combat diabetes but demonstrating significant contributions to weight loss. This shift is critical in addressing the global health challenge posed by obesity. However, there are concerns about the potential misuse of these medications.

The new drugs are built upon a component similar to the hormone glucagon, specifically GLP-1, produced by the intestine. GLP-1 enhances insulin secretion from the pancreas and signals satiety to the brain post-meals. Consequently, GLP-1-based medications are prescribed to address obesity or overweight conditions with comorbid factors.

Karen Clément, a professor of nutrition, notes unprecedented weight loss effects compared to other medications, approaching results seen in obesity surgery. However, she emphasizes that these medications do not cure the disease, and discontinuation can result in weight regain.

Health economist Frédéric Pizart views this as a substantial pharmaceutical and societal revolution but stresses the importance of caution, a standard practice with any new medicine. The medications, including semaglutide in Ozambik, face increasing demand, prompting pharmaceutical companies like Novo Nordisk to invest significantly in production facilities.

Concerns about shortages have led to counterfeit injections, raising alarms from health authorities. GLP-1 analogues, while effective, may cause side effects like nausea and gastrointestinal disorders.

Professor Karen Kleiman underscores the need for judicious and organized prescription due to past failures in the field. Long-term efficacy varies among individuals, posing a challenge. Additionally, the requirement for injections and the high cost of treatment, such as a thousand dollars per month in the U.S., are notable drawbacks.

Leading pharmaceutical companies, such as Novo Nordisk and Eli Lilly, have emerged as major beneficiaries, with substantial market values. Investments in the billions are underway to meet the rising demand for obesity treatment.

The World Obesity Federation predicts that approximately two billion people worldwide will suffer from obesity by 2035, prompting ongoing developments in treatment solutions. Professor Kleiman anticipates future drugs combining two or three hormones, reflecting a shift toward satiety hormones rather than traditional appetite suppressants. In Lyon, the biotechnology company Adosia is developing an insulin combined with amylin to address weight gain associated with insulin use in people with type 1 diabetes. According to Olivier Sola, the company’s head, this marks a new era focused on satiety hormones.

This news has been read 887 times!